Immunology & Rheumatology

Uncovering the cause of regulatory T cell dysfunction in elderly-onset rheumatoid arthritis

byUniversity of TsukubaGraphical abstract. Credit:Clinical Immunology(2024). DOI: 10.1016/j.clim.2024.110337Researchers at Tsukuba University have discovered that the increase in reg

Updated on: September 02,2024

Uncovering the cause of regulatory T cell dysfunction in elderly-onset rheumatoid arthritis

byUniversity of TsukubaGraphical abstract. Credit:Clinical Immunology(2024). DOI: 10.1016/j.clim.2024.110337Researchers at Tsukuba University have discovered that the increase in reg

Updated on:September 02,2024

A stealthy way to combat tumors

by Anne Trafton,Massachusetts Institute of TechnologyMIT researchers have identified a specialized subset of dendritic cells that help stimulate T cells to attack tumors. In this image, the blue

Updated on: May 07,2024

A stealthy way to combat tumors

by Anne Trafton,Massachusetts Institute of TechnologyMIT researchers have identified a specialized subset of dendritic cells that help stimulate T cells to attack tumors. In this image, the blue

Updated on:May 07,2024

Chip identifies rhinoviruses as cause of asthma

by Medical University of ViennaCredit: Medical University of ViennaMedUni Vienna has developed a method that can be used to identify individual rhinovirus strains ("cold viruses") as a

Updated on: April 09,2024

Chip identifies rhinoviruses as cause of asthma

by Medical University of ViennaCredit: Medical University of ViennaMedUni Vienna has developed a method that can be used to identify individual rhinovirus strains ("cold viruses") as a

Updated on:April 09,2024

COVID infection may boost antibodies for up to 20 months

If you've already had COVID-19, your natural antibodies may last as long as 20 months, a new study suggests.While this is reassuring, experts are quick to caution that the new findings don't n

Updated on: April 13,2024

COVID infection may boost antibodies for up to 20 months

If you've already had COVID-19, your natural antibodies may last as long as 20 months, a new study suggests.While this is reassuring, experts are quick to caution that the new findings don't n

Updated on:April 13,2024

Study finds antibody-associated vasculitis characteristics and treatments vary across lifespan

by American College of RheumatologyMedications ever received by patients with granulomatosis with polyangiitis and microscopic polyangiitis stratified by age at diagnosis. Credit: The Association

Updated on: May 08,2024

Study finds antibody-associated vasculitis characteristics and treatments vary across lifespan

by American College of RheumatologyMedications ever received by patients with granulomatosis with polyangiitis and microscopic polyangiitis stratified by age at diagnosis. Credit: The Association

Updated on:May 08,2024

Study finds COVID-19 vaccine not associated with severe disease flare in patients with rheumatic diseases

by American College of RheumatologyCredit: Unsplash/CC0 Public DomainNew research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the

Updated on: June 17,2024

Study finds COVID-19 vaccine not associated with severe disease flare in patients with rheumatic diseases

by American College of RheumatologyCredit: Unsplash/CC0 Public DomainNew research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the

Updated on:June 17,2024

Fracture risk down with adherence to bisphosphonates

For patients with an osteoporotic fracture, adherence to bisphosphonate treatment is associated with reduced fracture risk; and for veterans with rheumatoid arthritis, non-adherence to bisphosphonate

Updated on: March 24,2024

Fracture risk down with adherence to bisphosphonates

For patients with an osteoporotic fracture, adherence to bisphosphonate treatment is associated with reduced fracture risk; and for veterans with rheumatoid arthritis, non-adherence to bisphosphonate

Updated on:March 24,2024

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLC

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLCby International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public Domai

Updated on: September 25,2024

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLC

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLCby International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public Domai

Updated on:September 25,2024

Risk score predicts disease progression in patients with rheumatoid arthritis

by WileyCredit: Unsplash/CC0 Public DomainScientists have created a risk score based on thousands of genetic variants to determine the prognosis of individual patients with rheumatoid arthritis.I

Updated on: June 17,2024

Risk score predicts disease progression in patients with rheumatoid arthritis

by WileyCredit: Unsplash/CC0 Public DomainScientists have created a risk score based on thousands of genetic variants to determine the prognosis of individual patients with rheumatoid arthritis.I

Updated on:June 17,2024

Redundancies in T cells

by Fabio Bergamin,ETH ZurichCredit: AI-generated imageResearchers at ETH Zurich have discovered redundancies in the biochemical signalling pathways of immune cells. This finding has important im

Updated on: May 05,2024

Redundancies in T cells

by Fabio Bergamin,ETH ZurichCredit: AI-generated imageResearchers at ETH Zurich have discovered redundancies in the biochemical signalling pathways of immune cells. This finding has important im

Updated on:May 05,2024

Researchers identify new target for rheumatoid arthritis

by Hospital for Special SurgeryCo-senior author and Program Director Carl Blobel, M.D., Ph.D., works with collaborator Lionel Ivashkiv, M.D., in the Arthritis and Tissue Degeneration Program lab